Objective To observe the reversion of multi-drug resistance by proteasome inhibitor
bortezomib in K562/DNR cell line and to analyze the possible mechanism of reversion of …

Abstract 3595 The overexpression of proteasomes and constitutive activation of NF-KB in
acute myeloid leukemia (AML) cells suggest that proteasome inhibitors (PI) such as …

The proteasome inhibitor bortezomib has been shown to possess promising antitumor
activity and significant efficacy against a variety of malignancies. Different studies …

Proteasome inhibitors represent a new class of antineoplastic drugs that are considered in
the treatment of haematological malignancies. We compared the effects of the reversible …

Bortezomib (BZ) is the first clinically approved proteasome inhibitor that has shown
remarkable anticancer activity in patients with hematological malignancies. However, many …

Background Proteasome inhibition results in antitumor activity through various mechanisms,
including disruption of cell cycle progression and control, induction of apoptosis, and …

To study the mechanism of acquired resistance to bortezomib, a new antitumor drug that is
the first therapeutic proteasome inhibitor, we established a series of bortezomib-resistant T …

The multiple cellular targets affected by proteasome inhibition implicate a potential role for
bortezomib, a first-in-class proteasome inhibitor, in enhancing antitumor activities in …

The purpose of this study was to investigate the antitumor effects and drug interactions of the
proteasome inhibitor Bortezomib against high-risk myelodysplastic syndrome (MDS) cells in …

The nuclear factor-κ B (NF-κ B) transcription factor plays a pivotal role in diverse biological
processes including immune responses, inflammation, apoptosis, lymphocyte development …